Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H2 2017’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)

The report reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Kidney Disease (Chronic Renal Failure) therapeutics and enlists all their major and minor projects

The report assesses Chronic Kidney Disease (Chronic Renal Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allena Pharmaceuticals Inc

Angion Biomedica Corp

apceth Biopharma GmbH

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

Boehringer Ingelheim GmbH

Boryung Pharmaceutical Co Ltd

Cellmid Ltd

Chugai Pharmaceutical Co Ltd

Corvidia Therapeutics

CTI BioPharma Corp

Evotec AG

Gilead Sciences Inc

GNI Group Ltd

Lupin Ltd

Merck & Co Inc

Navya Biologicals Pvt Ltd

Nippon Zoki Pharmaceutical Co Ltd

Novartis AG

OPKO Health Inc

Otsuka Holdings Co Ltd

Prolong Pharmaceuticals LLC

ProMetic Life Sciences Inc

Reata Pharmaceuticals Inc

Relypsa Inc

Resverlogix Corp

Sarfez Pharmaceuticals Inc

Spotlight Innovation Inc

Taisho Pharmaceutical Holdings Co Ltd

Toray Industries Inc

Tricida Inc

Unity Biotechnology Inc

Vascular BioSciences

VESSL Therapeutics Ltd

Vicore Pharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Chronic Kidney Disease (Chronic Renal Failure) - Overview 8

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 22

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 29

Allena Pharmaceuticals Inc 29

Angion Biomedica Corp 29

apceth Biopharma GmbH 30

Astellas Pharma Inc 30

AstraZeneca Plc 31

Bayer AG 31

Boehringer Ingelheim GmbH 32

Boryung Pharmaceutical Co Ltd 32

Cellmid Ltd 33

Chugai Pharmaceutical Co Ltd 33

Corvidia Therapeutics 34

CTI BioPharma Corp 34

Evotec AG 35

Gilead Sciences Inc 35

GNI Group Ltd 36

Lupin Ltd 36

Merck & Co Inc 37

Navya Biologicals Pvt Ltd 37

Nippon Zoki Pharmaceutical Co Ltd 38

Novartis AG 38

OPKO Health Inc 39

Otsuka Holdings Co Ltd 39

Prolong Pharmaceuticals LLC 40

ProMetic Life Sciences Inc 40

Reata Pharmaceuticals Inc 41

Relypsa Inc 41

Resverlogix Corp 42

Sarfez Pharmaceuticals Inc 42

Spotlight Innovation Inc 43

Taisho Pharmaceutical Holdings Co Ltd 43

Toray Industries Inc 44

Tricida Inc 44

Unity Biotechnology Inc 44

Vascular BioSciences 45

VESSL Therapeutics Ltd 45

Vicore Pharma AB 46

Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles 47

ALLN-346 - Drug Profile 47

ambrisentan - Drug Profile 48

ANG-3070 - Drug Profile 51

ANG-3281 - Drug Profile 52

ANG-3586 - Drug Profile 53

ANG-4201 - Drug Profile 54

apabetalone - Drug Profile 55

AS-2444697 - Drug Profile 69

bardoxolone methyl - Drug Profile 70

BAY-1101042 - Drug Profile 77

BI-655088 - Drug Profile 78

BKE-001 - Drug Profile 79

BMP-7 - Drug Profile 80

C-21 - Drug Profile 82

CAB-101 - Drug Profile 86

calcium succinate - Drug Profile 88

CAR Peptide - Drug Profile 89

cardiotoxin - Drug Profile 90

Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile 91

COR-001 - Drug Profile 93

CTA-091 - Drug Profile 94

dapagliflozin propanediol - Drug Profile 95

Drug for Kidney Diseases - Drug Profile 104

Drug to Inhibit Chymase for Chronic Kidney Disease - Drug Profile 105

EOS-789 - Drug Profile 106

F-351 - Drug Profile 107

KBP-5074 - Drug Profile 109

MK-3866 - Drug Profile 111

Monoclonal Antibodies to Inhibit KITLG for Genito Urinary System and Sex Hormones, Immunology and Respiratory Diseases - Drug Profile 112

MultiGeneGraft - Drug Profile 113

NAV-003 - Drug Profile 114

NZ-419 - Drug Profile 115

pacritinib - Drug Profile 116

patiromer sorbitex calcium - Drug Profile 130

PBI-4050 - Drug Profile 134

Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile 143

Sanguinate - Drug Profile 144

Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile 147

Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease - Drug Profile 148

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile 149

Small Molecules for Chronic Kidney Disease - Drug Profile 150

Small Molecules for Chronic Kidney Disease - Drug Profile 151

Small Molecules to Inhibit CYP11B2 for Chronic Kidney Disease - Drug Profile 152

Small Molecules to Inhibit LGALS3 for Cardiovascular, Respiratory and Genito Urinary System Disorders - Drug Profile 153

SP-20103 - Drug Profile 154

SPR-494 - Drug Profile 155

Stem Cell Therapy for Chronic Kidney Disease - Drug Profile 156

Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease - Drug Profile 157

Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 158

tesidolumab - Drug Profile 159

tolvaptan - Drug Profile 161

torsemide ER - Drug Profile 166

TPX-200 - Drug Profile 167

TRC-101 - Drug Profile 168

TS-143 - Drug Profile 170

verinurad - Drug Profile 171

Vida-5 - Drug Profile 174

VS-105 - Drug Profile 175

Wnt-001 - Drug Profile 176

YS-1402 - Drug Profile 177

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 178

Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 181

Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones 182

Featured News & Press Releases 182

Appendix 193

Methodology 193

Coverage 193

Secondary Research 193

Primary Research 193

Expert Panel Validation 193

Contact Us 193

Disclaimer 194

List of Tables

List of Tables

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Allena Pharmaceuticals Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Angion Biomedica Corp, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by apceth Biopharma GmbH, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Astellas Pharma Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by AstraZeneca Plc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Bayer AG, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Boehringer Ingelheim GmbH, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Cellmid Ltd, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Corvidia Therapeutics, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by CTI BioPharma Corp, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Evotec AG, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Gilead Sciences Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by GNI Group Ltd, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Lupin Ltd, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Merck & Co Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Navya Biologicals Pvt Ltd, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Novartis AG, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by OPKO Health Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Otsuka Holdings Co Ltd, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Prolong Pharmaceuticals LLC, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by ProMetic Life Sciences Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Reata Pharmaceuticals Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Relypsa Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Resverlogix Corp, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Sarfez Pharmaceuticals Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Spotlight Innovation Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Toray Industries Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Tricida Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Unity Biotechnology Inc, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Vascular BioSciences, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by VESSL Therapeutics Ltd, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Vicore Pharma AB, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects, H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects, H2 2017 (Contd..1), H2 2017

Chronic Kidney Disease (Chronic Renal Failure) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports